HomeAI · summaries
Storia in 5 fonti
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary…
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary…
- ·
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in…
